Psychopharmacologic Treatment of Behavioral and Psychological Symptoms of Dementia
| Registration |
|---|
Before enrolling in this educational activity, you must log in or create an account. Once you register for the course, you will have 30 days from the date of enrollment to complete the course. The date your access expires will be indicated in the Course Summary box on this webpage. |
Target Audience
Healthcare professionals.
Educational Need
Managing the behavioral and psychological symptoms of dementia can be challenging, requiring clinicians to stay current on effective and safe treatment approaches. Education is needed to strengthen understanding of symptom types, appropriate psychopharmacologic options, and the associated risks and adverse effects of these treatments.
Learning Objectives
- Describe the various types of behavioral and psychological symptoms of dementia.
- Discuss psychopharmacologic treatments for the behavioral and psychological symptoms of dementia.
- Explore some of the risks and adverse effects related to psychopharmacologic treatments used to treat people who have dementia.
Speaker

Douglas Steenblock, MD
Chief of Mental Health Services, Iowa Veterans Home
Terms of Use and Privacy Policy
Recording date: October 17, 2025
Date of original release: October 17, 2025
Most recent review/update: October 17, 2025
Termination date: October 16, 2028
Accreditation Statements
- MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS). Des Moines University Medicine and Health Sciences (DMU) is accredited by the IMS to provide continuing medical education for physicians. DMU designates this enduring materials activity for 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- DO: Des Moines University Medicine and Health Sciences (DMU) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. DMU designates this activity for a maximum of 1.0 AOA Category 2-B credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
- Other healthcare providers: This activity is designated for 1.0 AMA PRA Category 1 Credit(s)™.
![]() | ![]() |
Educational Grants
No ineligible company provided financial support for this continuing education activity.
Disclosures
The speaker(s) will disclose if any pharmaceuticals, medical procedures, or devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). The activity director is responsible for determining educational content and selecting speakers.
Relevant to the content of this educational activity, the following individual does not have a financial relationship with an ineligible company; however, he intends to discuss the off-label use of a commercial product or device and agrees to inform learners. All relevant financial relationships have been mitigated.
- Douglas Steenblock, MD - Speaker
Disclaimer
The information provided in this activity is for continuing education purposes only. It is not a substitute for a healthcare provider's independent medical judgment regarding diagnostic and treatment options for a specific patient's medical condition.
Available Credit
- 1.00 AMA PRA Category 1 Credits™
- 1.00 AOA Category 2B
- 1.00 CE Contact Hour(s)

Facebook
X
LinkedIn
Forward
